Clinical trial
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for…
NCT00149981 · Novartis Pharmaceuticals, Industry · No longer available
Key facts
| NCT number | NCT00149981 |
|---|---|
| Title | A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation |
| Official title | A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | No longer available |
| Study type | Expanded Access |
| Conditions | Organ Transplantation |
| Intervention type | Drug |
| Interventions | everolimus (RAD) |
| First posted | Sep 8, 2005 |
| Last update posted | Sep 9, 2019 |
| Countries | Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Italy, New Zealand, Norway, Poland, Puerto Rico and 7 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: